Despite pricing outcry, branded pharma kept double-digit hikes coming in 2016: report
FiercePharma | May 10, 2017
Even amid a series of high-profile pricing controversies—and as a few companies made public promises to limit hikes—the pharma industry continued to raise list prices at rates far above general inflation, a new report shows.